Patents Assigned to Nevro Corp.
  • Patent number: 11602634
    Abstract: Systems and methods for using sensory threshold and/or adaptation for neurological therapy screening and/or parameter selection. A representative method for establishing a treatment regimen for a patient includes: in response to a first indication of a characteristic of the patient's sensory response to an electrical stimulus, providing a second indication indicating suitability of an electrical signal for delivery to the patient to address a patient condition, wherein the electrical signal has a frequency in a frequency range from 1.2 kHz to 100 kHz.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: March 14, 2023
    Assignee: Nevro Corp.
    Inventor: Dongchul Lee
  • Patent number: 11596798
    Abstract: Systems and methods for treating congestive heart failure with high frequency stimulation are disclosed. A representative method for treating a patient includes applying an electrical signal having a frequency of from about 1 kHz to about 100 kHz to the patient via a treatment system that includes a signal delivery element in electrical communication with the patient's vagus nerve at a portion of the vagus nerve located at or proximate to the anterior interventricular junction of the patient's heart. The method can further include automatically detecting at least one physiological parameter of the patient, automatically determining at least one of an ejection fraction of the patient's heart and a correlate of the ejection fraction based on the detected parameter, and automatically adjusting the applied signal based on the determined ejection fraction.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: March 7, 2023
    Assignee: Nevro Corp
    Inventors: James R. Thacker, Kerry Bradley
  • Patent number: 11590352
    Abstract: Systems and methods for treating a patient's pain using ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods are disclosed. A representative method for treating a patient includes positioning an implantable signal delivery device proximate to a target location at or near the patient's spinal cord, and delivering an electrical therapy signal to the target location via the implantable signal delivery device, wherein the electrical therapy signal has a frequency in a frequency range of from about 1 kHz to about 100 kHz, and wherein the frequency is increased or decreased from a first value to a second value during delivery.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: February 28, 2023
    Assignee: Nevro Corp.
    Inventors: Dongchul Lee, Kerry Bradley, Kwan Yeop Lee
  • Patent number: 11571570
    Abstract: A power control circuit for use with devices that will be placed in a flammable sterilizing gas includes a bi-stable switch that is configured to produce an output to place the circuitry of a connected device in a run state or a sleep state. The bi-stable switch controls one or more transistors to drain energy from energy storage devices in the circuitry of the connected device to a level below an ignition level of a sterilizing gas. A remotely actuatable switch can be actuated from outside of a packaging in which the power control circuit is placed to cause the bi-stable switch to produce an output that puts the circuitry in the run state without removing the power control circuit from the packaging.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: February 7, 2023
    Assignee: Nevro Corp.
    Inventor: Bret Foreman
  • Patent number: 11534611
    Abstract: Systems and methods for treating a patient having a blood glucose abnormality, such as type 2 diabetes (T2D), using an electrical signal are disclosed. A representative method for treating a patient includes, based at least in part on a patient indication of a blood glucose abnormality, positioning at least one implantable signal delivery device proximate to a target location at the patient's spinal cord within a vertebral range of from about C8 to about T12. The method further includes directing an electrical signal to the target location via the implantable signal delivery device, wherein the electrical signal has a frequency in a frequency range of from 1.2 kHz to 100 kHz.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: December 27, 2022
    Assignee: Nevro Corp.
    Inventors: Daniel Baldoni, Satinderpall Singh Pannu
  • Patent number: 11458317
    Abstract: Variable amplitude signals for neurological therapy, and associated systems and methods are disclosed. A representative method includes activating automatic delivery of an electrical therapy signal to a patient's spinal cord region at a frequency in a frequency range between 1.5 kHz and 100 kHz, via at least one signal delivery contact carried by an implanted signal delivery device. The delivery can include repeatedly and automatically delivering the electrical therapy signal at each of multiple therapy signal amplitudes to the at least one signal delivery contact, without the therapy signal generating paresthesia in the patient. The foregoing process can be used as a screening tool to screen responders from non-responders in the context of a non-paresthesia-generating therapy, and/or can be used during long-term treatment, for example, for chronic pain.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 4, 2022
    Assignee: Nevro Corp.
    Inventor: Chris Dawson
  • Patent number: 11446504
    Abstract: Electromagnetic stimulation for treating diseases, conditions associated with diseases and/or inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, high-frequency stimulation in the range of from about 1.5 kHz to about 100 kHz may be applied to a patient's target tissue region to treat the disease, associated condition and/or to inhibit pain. Electrical stimulation in accordance with similar parameters can directly affect a cellular membrane, such as a neuron and in particular, a spontaneously active neuron and/or a quiescent neuron.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: September 20, 2022
    Assignee: Nevro Corp.
    Inventor: Dongchul Lee
  • Patent number: 11420045
    Abstract: The present technology is generally directed to spinal cord modulation leads having one or more sidewall openings configured for inserting stylets to steer and/or position the leads within a patient and/or with respect to a pulse generator, and associated systems and methods. In some embodiments, sidewall opening is generally positioned in an intermediate portion of the lead and is operatively coupled to a lumen extending distally to a distal end of the lead, and/or proximally to a proximal end of the lead.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: August 23, 2022
    Assignee: Nevro Corp.
    Inventors: Pankaj Sunkeri, Apratim N. Dixit
  • Patent number: 11389647
    Abstract: A lead anchor comprising a longitudinally extending anchor body and a retainer. The longitudinally extending anchor body having a lumen positioned to receive a spinal cord lead therethrough and having a retainer pocket intersecting the lumen. The retainer is positioned in the retainer pocket. The retainer comprises a first grip member having at least one first aperture, a second grip member having at least one second aperture, and at least one U-shaped resilient portion connecting the first and second grip members.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: July 19, 2022
    Assignee: Nevro Corp.
    Inventor: Mark Steven Wong
  • Patent number: 11382531
    Abstract: Systems and methods for positioning implanted devices in a patient are disclosed. A method in accordance with a particular embodiment includes, for each of a plurality of patients, receiving a target location from which to deliver a modulation signal to the patient's spinal cord. The method further includes implanting a signal delivery device within a vertebral foramen of each patient, and positioning an electrical contact carried by the signal delivery device to be within ±5 mm. of the target location, without the use of fluoroscopy. The method can still further include, for each of the plurality of patients, activating the electrical contact to modulate neural activity at the spinal cord. In further particular embodiments, RF signals, ultrasound, magnetic fields, and/or other techniques are used to locate the signal delivery device.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 12, 2022
    Assignee: Nevro Corp.
    Inventors: James R. Thacker, Jon Parker, Yougandh Chitre
  • Patent number: 11318310
    Abstract: Electrical stimulation, including high frequency stimulation, for altering autonomic functions, and associated systems and methods are disclosed. A representative method includes directing an electrical signal to a target tissue at (a) a ventral region of the patient's spinal canal, (b) a sympathetic chain structure, or (c) both (a) and (b), at a frequency in a range from 1 kHz to 100 kHz, and an amplitude that does not generate an objectionable, patient-detectable sensation.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: May 3, 2022
    Assignee: Nevro Corp.
    Inventor: Kerry Bradley
  • Patent number: 11298539
    Abstract: Selective high-frequency spinal cord modulation for inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, high-frequency modulation in the range of from about 1.5 KHz to about 50 KHz may be applied to the patient's spinal cord region from an epidural, cervical location to address at least one of high back pain, mid-back pain, low back pain, and leg pain without creating paresthesia in the patient.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: April 12, 2022
    Assignee: Nevro Corp.
    Inventors: James R. Thacker, Konstantinos Alataris, Bradford Evan Gliner
  • Patent number: 11247057
    Abstract: Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods. A method for treating a patient in accordance with a particular embodiment includes selecting a neural modulation site to include a neural population of the patient's spinal cord, and selecting parameters of a neural modulation signal to at least reduce an autonomic system deficit in the patient.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: February 15, 2022
    Assignee: Nevro Corp.
    Inventor: Bradford Evan Gliner
  • Patent number: 11229792
    Abstract: Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods are disclosed. A representative method in accordance with an embodiment of the disclosure includes creating a therapeutic effect and a sensation in a patient by delivering to the patient first pulses having a first set of first signal delivery parameters and second pulses having a second set of second signal delivery parameters, wherein a first value of at least one first parameter of the first set is different than a second value of a corresponding second parameter of the second set, and wherein the first pulses, the second pulses or both the first and second pulses are delivered to the patient's spinal cord.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: January 25, 2022
    Assignee: Nevro Corp.
    Inventors: Konstantinos Alataris, Andre B. Walker, Jon Parker
  • Patent number: 11229793
    Abstract: Selective high-frequency spinal chord modulation for inhibiting pain with reduced side affects and associated systems and methods are disclosed. In particular embodiments, high-frequency modulation in the range of from about 1.5 KHz to about 50 KHz may be applied to the patient's spinal chord region to address low back pain without creating unwanted sensory and/or motor side affects. In other embodiments, modulation in accordance with similar parameters can be applied to other spinal or peripheral locations to address other indications.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: January 25, 2022
    Assignee: Nevro Corp.
    Inventors: Konstantinos Alataris, Andre B. Walker, Jon Parker, Yougandh Chitre, Sangsoo Wesley Park, James R. Thacker
  • Patent number: 11198001
    Abstract: Methods for automatically programming a signal generator in a patient therapy system and associated systems are disclosed. A representative method comprises retrieving data including therapy program parameters, level of efficacy, and medication use corresponding to a plurality of time periods; identifying from the data a target time period having a corresponding level of efficacy; determining from the data if medication was used during the target time period; determining from the data if medication was used during a prior time period immediately before the target time period; calculating a lead position confidence factor; and programming the signal generator to repeat therapy with the therapy program parameters corresponding to the target time period if the confidence factor is greater than a threshold value and medication was used during the prior time period and not during the target time period.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: December 14, 2021
    Assignee: Nevro Corp.
    Inventors: James R. Thacker, Jon Parker
  • Patent number: 11147974
    Abstract: The disclosed technology provides systems and methods of communication between implanted medical devices, e.g., implanted pulse generators, and handheld consumer devices, e.g., smartphones, via standard wireless communication protocols, e.g., Bluetooth or Bluetooth Low Energy (BLE) operating in the unlicensed 2.4 GHz frequency band.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 19, 2021
    Assignee: Nevro Corp.
    Inventors: Prabdeep Sandhu, Bret Foreman
  • Patent number: D947765
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: April 5, 2022
    Assignee: Nevro Corp.
    Inventor: Jerry O'Leary
  • Patent number: D964966
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: September 27, 2022
    Assignee: Nevro Corp.
    Inventor: Jerry O'Leary
  • Patent number: D984650
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: April 25, 2023
    Assignee: Nevro Corp.
    Inventors: Apratim Dixit, Ivan Tzvetanov, Cameron Karamian, Keith Daniel Alsberg, Jeremiah Peter O'Leary, Gary Harlan Paulsen, Omid Mashhadi